Divi's Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-16
Stock price
₹7316.00
Market cap
1,93,874 Cr
Stock P/E
71.5
P/B
11.57
Dividend yield
0.4%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,778 Cr | 3,687 Cr | 5,542 Cr | 7,845 Cr | 2,118 Cr | 4,456 Cr | 2,319 Cr | 2,585 Cr | 2,410 Cr | 2,715 Cr | 2,604 Cr | 2,831 Cr |
| Operating expenses (approx.) | 1,193 Cr | 2,537 Cr | 3,808 Cr | 5,301 Cr | 1,417 Cr | 2,933 Cr | 1,576 Cr | 1,613 Cr | 1,562 Cr | 1,682 Cr | 1,714 Cr | 1,742 Cr |
| EBITDA | 585 Cr | 1,150 Cr | 1,734 Cr | 2,544 Cr | 701 Cr | 1,523 Cr | 743 Cr | 972 Cr | 848 Cr | 1,033 Cr | 890 Cr | 1,089 Cr |
| OPM % | 32.9% | 31.2% | 31.3% | 32.4% | 33.1% | 34.2% | 32.0% | 37.6% | 35.2% | 38.0% | 34.2% | 38.5% |
| Other income | 81 Cr | 167 Cr | 262 Cr | 339 Cr | 79 Cr | 184 Cr | 82 Cr | 86 Cr | 119 Cr | 145 Cr | 88 Cr | 155 Cr |
| Interest | 0.0000 Cr | 1 Cr | 1 Cr | 3 Cr | 0.0000 Cr | 1 Cr | 0.0000 Cr | 1 Cr | 3 Cr | 8 Cr | 6 Cr | 6 Cr |
| Depreciation | 93 Cr | 188 Cr | 283 Cr | 378 Cr | 97 Cr | 196 Cr | 99 Cr | 107 Cr | 112 Cr | 113 Cr | 118 Cr | 120 Cr |
| Profit before tax | 492 Cr | 961 Cr | 1,450 Cr | 2,163 Cr | 604 Cr | 1,326 Cr | 726 Cr | 864 Cr | 733 Cr | 912 Cr | 780 Cr | 963 Cr |
| Tax % | 27.6% | 26.7% | 26.8% | 26.0% | 28.8% | 29.1% | 18.9% | 23.4% | 25.6% | 24.5% | 25.3% | 22.0% |
| Net profit | 356 Cr | 704 Cr | 1,062 Cr | 1,600 Cr | 430 Cr | 940 Cr | 589 Cr | 662 Cr | 545 Cr | 689 Cr | 583 Cr | 751 Cr |
| EPS (₹) | ₹13.41 | ₹26.52 | ₹40.02 | ₹60.27 | ₹16.20 | ₹35.40 | ₹22.20 | ₹24.93 | ₹20.49 | ₹25.97 | ₹21.98 | ₹28.31 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,946 Cr | 5,394 Cr | 6,969 Cr | 8,960 Cr | 7,768 Cr | 7,845 Cr | 9,360 Cr | 10,560 Cr | Sign in for TTM |
| Operating expenses (approx.) | 2,919 Cr | 3,383 Cr | 4,047 Cr | 4,964 Cr | 5,400 Cr | 5,640 Cr | 6,040 Cr | 6,686 Cr | Sign in for TTM |
| EBITDA | 2,027 Cr | 2,012 Cr | 2,923 Cr | 3,996 Cr | 2,368 Cr | 2,205 Cr | 3,320 Cr | 3,874 Cr | Sign in for TTM |
| OPM % | 41.0% | 37.3% | 41.9% | 44.6% | 30.5% | 28.1% | 35.5% | 36.7% | Sign in for TTM |
| Other income | 156 Cr | 190 Cr | 63 Cr | 114 Cr | 345 Cr | 339 Cr | 352 Cr | 507 Cr | Sign in for TTM |
| Interest | 4 Cr | 6 Cr | 0.87 Cr | 0.80 Cr | 0.67 Cr | 3 Cr | 2 Cr | 23 Cr | Sign in for TTM |
| Depreciation | 169 Cr | 186 Cr | 256 Cr | 312 Cr | 343 Cr | 378 Cr | 402 Cr | 463 Cr | Sign in for TTM |
| Profit before tax | 1,855 Cr | 1,819 Cr | 2,666 Cr | 3,684 Cr | 2,369 Cr | 2,163 Cr | 2,916 Cr | 3,388 Cr | Sign in for TTM |
| Tax % | 27.1% | 24.3% | 25.6% | 19.6% | 23.0% | 26.0% | 24.9% | 24.2% | Sign in for TTM |
| Net profit | 1,353 Cr | 1,377 Cr | 1,984 Cr | 2,960 Cr | 1,823 Cr | 1,600 Cr | 2,191 Cr | 2,568 Cr | Sign in for TTM |
| EPS (₹) | ₹50.96 | ₹51.85 | ₹74.75 | ₹111.52 | ₹68.69 | ₹60.27 | ₹82.53 | ₹96.75 | Sign in for TTM |
| Dividend payout % | — | — | — | 17.9% | 43.7% | 49.8% | 36.3% | 31.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr | 53 Cr |
| Reserves | 6,904 Cr | 7,257 Cr | 9,242 Cr | 11,675 Cr | 12,714 Cr | 13,518 Cr | 14,916 Cr | 16,708 Cr |
| Borrowings | — | — | — | — | — | — | 2 Cr | — |
| Other liabilities | — | — | — | — | 1,672 Cr | 1,899 Cr | 1,961 Cr | 3,272 Cr |
| Total liabilities | — | — | — | — | 14,439 Cr | 15,470 Cr | 16,932 Cr | 20,033 Cr |
| Fixed assets (net) | — | — | — | — | 4,714 Cr | 4,733 Cr | 5,437 Cr | 6,515 Cr |
| CWIP | — | — | — | — | 212 Cr | 778 Cr | 1,022 Cr | 2,113 Cr |
| Investments | — | — | — | — | 77 Cr | 82 Cr | 65 Cr | 69 Cr |
| Other assets | — | — | — | — | 9,312 Cr | 9,675 Cr | 10,081 Cr | 11,096 Cr |
| Total assets | — | — | — | — | 14,439 Cr | 15,470 Cr | 16,932 Cr | 20,033 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 1,912 Cr | 2,460 Cr | 1,261 Cr | 1,653 Cr | 2,738 Cr |
| Cash from investing | — | — | — | -2,195 Cr | -2,708 Cr | -269 Cr | -804 Cr | -2,219 Cr |
| Cash from financing | — | — | — | -532 Cr | -797 Cr | -799 Cr | -799 Cr | -804 Cr |
| Net cash flow | — | — | — | -816 Cr | -1,045 Cr | 193 Cr | 50 Cr | -285 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 1,199 Cr | 1,987 Cr | 258 Cr | 215 Cr | 218 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 26.7% | 25.0% | 28.7% | 31.4% | 15.9% | 13.5% | 19.5% | 20.4% |
| ROE % | 0.0% | 18.8% | 21.3% | 25.2% | 14.3% | 11.8% | 14.6% | 15.3% |
| Debtor days | — | — | — | — | 84 | 100 | 106 | — |
| Inventory days | — | — | — | — | 363 | 360 | 308 | 329 |
| Days payable | — | — | — | — | 92 | 93 | 87 | — |
| Cash conversion cycle | — | — | — | — | 355 | 367 | 328 | 329 |
| Debt / equity | — | — | — | — | — | — | 0.0001 | — |
| Current ratio | — | — | — | — | 8.46 | 7.57 | 6.94 | 5.43 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -0.07 | -0.16 | -0.12 | -0.03 |
Compare with peers
Loading peers…